1. Klastersky J, De Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol.
2016 ; 27(suppl_5):111-8.
2.Paul M, Yahav D, Fraser A, Leibovici LJJoac. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2005;57(2):176-89.
3.Lehrnbecher T, Phillips R, Alexander S, Alvaro F, Carlesse F, Fisher B, et al. Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation. J Clin Oncol. 2012;30(35):4427-38.
4.Rosa RG, Goldani LZJPO. Factors associated with hospital length of stay among cancer patients with febrile neutropenia. PLoS One.2014;9(10):e108969.
5.De Naurois J, Novitzky-Basso I, Gill M, Marti FM, Cullen M, Roila F, et al. Management of febrile neutropenia: ESMO clinical practice guidelines. 2010;21(suppl_5):252-6.
6.Klastersky J, Paesmans M, Aoun M, Georgala A, Loizidou A, Lalami Y, et al. Clinical research in febrile neutropenia in cancer patients: Past achievements and perspectives for the future. World J Clin Infect Dis. 2016; 6(3):37-60.
7.Mendes AVA, Sapolnik R, Mendonça NJJdP. New guidelines for the clinical management of febrile neutropenia and sepsis in pediatric oncology patients. J Pediatr. 2007;83(2):S54- S63.
8.Rasmy A, Amal A, Fotih S, Selwi WJJCPCR. Febrile neutropenia in cancer patient: epidemiology, microbiology, pathophysiology and management. J Cancer Prev Curr Res 2016;5(3):00165.
9.Maxwell RR, Egan‐Sherry D, Gill JB, Roth MEJPb, cancer. Management of chemotherapy‐induced febrile neutropenia in pediatric oncology patients: A North American survey of pediatric hematology/oncology and pediatric infectious disease physicians. Pediatr Blood Cancer. 2017;64(12):e26700.
10.Biswal S, Godnaik CJE. Incidence and management of infections in patients with acute leukemia following chemotherapy in general wards. Ecancermedicalscience. 2013;7:310
11.Llamas RMH, Acosta MEH, Silva JD. Management of febrile neutropenia in pediatric cancer patients. J Pediatr Neonatal Care. 2019;9(1):22-6.
12.Alam MM. Composite Adverse Event Outcome in Pediatric Cancer Patients with Prolonged Febrile Neutropenia. J Microbiol Infect Dis. 2016;6(2):69-73
13.Ottonello L, Dapino P, Pastorino G, Dallegri F, Sacchetti CJEjoci. Neutrophil dysfunction and increased susceptibility to infection. Eur J Clin Invest. 1995;25(9):687-92.
14.Helaly L, Sarker MZH, Mannan M, Hossain MT, Ahmed S, Begum MJNIMCJ. Comparative study between two empirical antibiotic regime in the management of childhood malignancy with fever. Northern International Medical College Journal. 2014;5(2):329-31.
15.Kebudi R, Kizilocak HJCpr. Febrile neutropenia in children with cancer: approach to diagnosis and treatment. Curr Pediatr Rev.2018;14(3):204-9.
16.Rabagliati R, Bidart T, Payá E, Guzmán AM, Morales R, Braun S, et al. Consenso manejo racional del paciente con cáncer, neutropenia y fiebre: rational approach towards the patient with cancer, fever and neutropenia. Rev Chilena Infectol. 2005;22:79-113.
17.Lal A, Bhurgri Y, Rizvi N, Virwani M, Memon RU, Saeed W, et al. Factors influencing in- hospital length of stay and mortality in cancer patients suffering from febrile neutropenia. Asian Pac J Cancer Prev. 2008;9(2):303.
18.Pizzo PAJAoim. Management of patients with fever and neutropenia through the arc of time: a narrative review.Ann Intern Med. 2019;170(6):389-97.
19.Lehrnbecher TJCoip. Treatment of fever in neutropenia in pediatric oncology patients. . Curr Opin Pediatr.2019;31(1):35-40.
20.Wagner S, Brack EK, Stutz-Grunder E, Agyeman P, Leibundgut K, Teuffel O, et al. The influence of different fever definitions on diagnostics and treatment after diagnosis of fever in chemotherapy-induced neutropenia in children with cancer. PLoS One 2018;13(2):e0193227.